---
title: Accelerating mRNA-Based Therapy Development with Scalable Purification of In Vitro Transcribed mRNA
description: Learn more about the new Thermo Scientific POROS Oligo (dT)25 affinity chromatography resin for the purification of IVT mRNA.
---

[![BPI Media_Logo 2_Color 1](https://bpi.bioprocessintl.com/hs-fs/hubfs/BPI%20Media_Logo%202_Color%201.png?width=350&height=161&name=BPI%20Media_Logo%202_Color%201.png)](https://bioprocessintl.com/)

 

---

![New-ATE-Logo2019](https://bpi.bioprocessintl.com/hs-fs/hubfs/New-ATE-Logo2019.png?width=700&name=New-ATE-Logo2019.png)

This webcast can now be viewed on-demand: [Click here.](https://bioprocessintl.com/sponsored-content/accelerating-mrna-based-therapy-development-with-scalable-purification-of-in-vitro-transcribed-mrna/)

---

## Accelerating mRNA-Based Therapy Development with Scalable Purification of In Vitro Transcribed mRNA

## Presenter:

**![kelly flook - updated image](https://bpi.bioprocessintl.com/hs-fs/hubfs/kelly%20flook%20-%20updated%20image.jpg?width=150&name=kelly%20flook%20-%20updated%20image.jpg)Kelly Flook**

Senior Product Manager, Purification Products

Thermo Fisher Scientific

 

Kelly Flook is Senior Product Manager for purification products within the Bioproduction Division at Thermo Fisher Scientific. Kelly has a PhD in polymer and analytical chemistry from the University of Durham, UK. During her 15 years at Thermo Fisher, Kelly has gained extensive experience in product development across all scales of chromatography and related biological workflows. Kelly has a strong expertise in bead technology and bioseparations. Drawing from a diverse technical background, in her current role Kelly is responsible for new product development and commercialization of solutions across the downstream workflow.

## About this event:

#### Date: September 23, 2020

#### Time: 11 am EDT | 8 am PDT | 5 pm CEST

#### Duration: 15 minutes

 

 The diversity of potential mRNA-based therapies has led to increased interest in using synthetic mRNA as a tool in the treatment of multiple diseases, such as cancer, stem cell therapies, and infectious diseases. Nevertheless, obtaining larger quantities of synthetic mRNA for clinical treatment remains a challenge. Currently available mRNA purification methods are becoming a bottleneck for large-scale manufacture as the limits of research-scale purification techniques are realized. Affinity chromatography, a highly scalable method, has earned its credits in the development of biologics such as the use of Protein A for the purification of therapeutic antibodies and more recently anti-AAV resins in gene therapy workflows. An effective affinity purification step can help to simplify biomolecule downstream processing, reduce the number of purification steps, and reduce the overall cost of goods in biotherapeutic manufacturing.

 

Here we present our new affinity-based mRNA chromatography resin, specifically developed for the purification and isolation of mRNA from in vitro transcription (IVT) manufacturing processes.

**Learning points:**

- Learn more about the new Thermo Scientific™ POROS™ Oligo (dT)25 affinity chromatography resin for the purification of IVT mRNA.
- Understand how affinity chromatography can help to simplify workflows and maximize efficiency of your mRNA purification process.

|   |   |
| --- | --- |

 

-  

-  

©2015 BioProcess International All Rights reserved